UPC Analytics
DEEN
Übersicht · Eingereicht: —

ACT_589997/2023

System for ambulatory drug infusion comprising a filling apparatus for flexible containers

NichtigkeitHauptnichtigkeitsklageParis CDRevocation Action—
ÜbersichtEntscheidungenBegründungDokumenteZeitverlauf
Abdeckung: Teilweise.Begründung teilweise extrahiert — einige Abschnitte können unvollständig sein.
Zusammenfassung in einfacher Sprache

Tandem Diabetes Care sought revocation of Roche's EP 2 196 231 (ambulatory drug infusion system with filling apparatus for flexible containers). The Paris Central Division rejected all invalidity attacks, finding that neither Diaz nor Robertson (alone or in combination), nor Glejboel combined with those references, disclosed the key feature requiring the support structure to limit container expansion (feature 1.3iii). The court also held that breach of a standstill agreement does not bar proceedings but may give rise to contractual liability, and maintained the patent as granted.

Angenommene Argumente
Was das Gericht akzeptiert hat — nach Partei.

  • Breach of a standstill clause does not deprive the breaching party of the right to sue, but may give rise to contractual liability

    Kläger

    Hinweis: The Paris Central Division rejected any jurisdictional/admissibility challenge based on breach of a standstill clause, holding such breaches do not divest the party of the right to bring an action.

  • Claim 1 feature 1.3iii (support structure limiting expansion of flexible container) is not disclosed by 'Diaz'

    BeklagterRechtsgrundlage: Art. 56 EPC

    Hinweis: The court found that Diaz's reservoir casing performs a protective function and the gap shown in figures is intended to remain even when filled, so the limitation feature is not disclosed.

  • Robertson (container for solid medicaments/pills) is not a relevant combination with Diaz (liquid drug delivery)

    BeklagterRechtsgrundlage: Art. 56 EPC

    Hinweis: The court found the skilled person would be unlikely to consult Robertson (a box for pills) to improve Diaz (a liquid medicament delivery system), and in any event Robertson does not disclose the missing feature.

Zurückgewiesene Argumente
Was das Gericht nicht akzeptiert hat — und warum.

  • Lack of inventive step over Diaz combined with Robertson

    KlägerRechtsgrundlage: Art. 56 EPC

    Begründung: Neither Diaz nor Robertson discloses feature 1.3iii (the support structure limiting container expansion), and the combination of the two references cannot supply this missing element; the skilled person would have had no motivation to combine the two documents.

  • Lack of inventive step starting from Glejboel combined with Diaz and/or Robertson

    KlägerRechtsgrundlage: Art. 56 EPC

    Begründung: Neither Glejboel, Diaz, nor Robertson discloses feature 1.3iii, so this combination also fails to establish obviousness.

Zentrale Rechtsgrundsätze
In der Begründung herangezogene Doktrinen und Regeln.
problem-solution approach for inventive stepstandstill clause breach does not bar action but may give rise to contractual liabilitymotivation to combine prior art references required for obviousness

Weitere Fälle zu diesem Grundsatz ansehen.

Herangezogener Stand der Technik
Zitierte Schriften und die Rolle, die sie gespielt haben.
  • Diaz (unspecified publication, liquid drug delivery system)Erfindungsmüh-Kombination
  • Robertson (unspecified publication, container for solid medicaments)Erfindungsmüh-Kombination
  • Glejboel (unspecified publication)Erfindungsmüh-Kombination
Hinweise zur Anspruchsauslegung

The court interpreted claim 1 of EP 2 196 231 as requiring a support structure that limits the expansion of the flexible container (feature 1.3iii). This feature was critical to the inventive step analysis: the court found that Diaz's reservoir casing, which surrounds the reservoir to protect medication, does not disclose this limiting function because the casing in Diaz is intended to leave a gap even when the reservoir is full.